Timely regeneration completion may limit harmful clones by reducing mobile DNA insertions
Late suppression of long interspersed nuclear element-1 (LINE-1) may preserve early epithelial repair while reducing new insertions and harmful clone expansion at equal total cell divisions. If a completion mimic remains beneficial when retrotransposition is nearly eliminated, its proposed determining role is refuted
Stage of verification
- Hypothesis published2026-10-05
- Indirect evidenceAssessed at 4 of 10
- Direct testAwaited
Map of the hypothesis
Hover over an icon or tap it to see its name.
Where in the body
Biological function
Kind of knowledge gap
A double ring marks the main placement where a group contains several values.
Target map
Every target of every published hypothesis, each with the actions a hypothesis can propose on it. The targets and the actions of this hypothesis are drawn solid.
Mobile element or insert
Retroelements
Mobile genetic elements whose activity can generate retroelement-derived nucleic acids
Where this hypothesis actsPersisting epithelial lineages during the late phase of tissue repair
Hypotheses on this target 3
Gene editing
Silencing2
Excision
Repair
What is proposed
Briefly suppress active LINE-1 during late tissue repair
HowUse antisense oligonucleotides directed at LINE-1 RNA while preserving the early regenerative response
Possible result
Possible reduction in new insertions, pathological clonal expansion and late tumour risk, with longer lifespan
From the recordКандидатный миметик — кратковременное подавление активных LINE-1 с помощью направленных на их РНК антисмысловых олигонуклеотидов в поздней фазе восстановления.
All targets of the lab
Every target read from the published hypotheses, each kind around its pictogram. A larger mark means more hypotheses act on that target. Point at a mark and the actions proposed on it branch out of it.
Solid and named: the targets of this hypothesis
Explore in depth
The logic
The train of thought that ends in this hypothesis. Each stage is the reason the next exists. The master question narrows to a goal, the goal to an unknown nobody has closed, the unknown to the hypothesis proposed here. Every step below says what it rests on and what carries it.
Finishing tissue repair at the right time might protect long-term health more than making repair stronger. The unexpected move is to imitate completion by briefly suppressing DNA sequences that can copy themselves into new positions, while preserving the initial repair response. This is a hypothesis generated by the pipeline, not a measured reduction in cancer or an observed extension of life.
- Prolonged repair is proposed to keep LINE-1 active in surviving tissue-lining cells.
- Active LINE-1 is proposed to add permanent DNA insertions during successive repair cycles.
- Some new insertions are proposed to give existing harmful cell groups additional changes that promote growth.
- Timely completion is proposed to switch cells from a repair state permitting LINE-1 activity to a mature state that suppresses it.
- Brief late treatment targeting LINE-1 RNA is proposed to imitate that suppression while preserving early recovery.
- Fewer consequential insertions are predicted to slow harmful cell-group expansion even when total cell divisions remain equal.
- Slower harmful expansion is proposed to reduce later cancer risk and thereby extend life.
Imagine a document repeatedly opened for revision while a faulty copy-and-paste command remains enabled. Disabling that command before each revision ends could prevent extra passages from accumulating without stopping the useful edits.
Where the picture breaks: Inserted DNA does not necessarily cause harm, and cells with different changes can survive or multiply differently. The picture therefore cannot establish either cancer risk or the proposal's separate assumption that rearranging the same repair cycles leaves accumulated risk unchanged.
- Master questionstep 01 of 04
Reproducing useful processes that normally occur in the body could offer new ways to extend life.
Rests on: The stated goal is to propose substances, combinations or other interventions that reproduce useful bodily processes and explain how they might extend life.
Stated in the chain - Goal pillarstep 02 of 04
The intended output is a defined set of new interventions that imitate bodily processes to extend life.
Rests on: The master question explicitly requests new hypotheses about which processes to reproduce and how.
Stated in the chain - Gap questionstep 03 of 04
Timely completion of tissue repair might extend life more than stronger repair if both provide equal early recovery but only completion limits later growth of harmful clones, groups of cells descended from a common ancestor.
Rests on: The preceding goal calls for interventions that imitate bodily processes, but does not identify repair completion as the process to choose or establish its proposed advantage.
LeapThe transition supplies no basis for expecting completion, rather than stronger repair, to uniquely restrict harmful cell groups at equal early recovery or to produce a greater lifespan benefit.
- Hypothesisstep 04 of 04
Shortening the period when LINE-1 can make new DNA copies during repair is proposed to reduce permanent genetic changes in epithelial cells, the cells lining tissue surfaces. Brief late treatment with antisense oligonucleotides, short manufactured strands that bind a chosen RNA message, would target LINE-1 RNA, the intermediate message used to make new copies. The predicted result is slower acquisition of changes that promote harmful growth and, eventually, lower cancer risk.
Rests on: The preceding question supplies the comparison between timely completion and stronger repair at equal early recovery. The hypothesis supplies renewed suppression of mobile DNA as its proposed completion function and borrows a cumulative-damage model from material fatigue.
AssumptionThe proposed explanation assumes that prolonged repair allows consequential new LINE-1 insertions in surviving epithelial cell families, that restoring suppression reduces those events, and that those events account for completion's advantage. The supplied sources do not establish those relationships.
What is carried, and what is not. The screened literature speaks directly to one link in the seven-item mechanism: cellular mechanisms can suppress LINE-1 copying. Scientific Reports (2018, S6) reported suppression by the DNA-repair protein Rad18 in laboratory 293T cells, and PLoS Genetics (2022, S7) reported suppression by the cellular protein MxB; neither establishes suppression during repair completion, the proposed treatment's effects in persistent tissue-lining cells, or the full sequence through harmful growth to longer life.S6S7
Where the reasoning is carried by something unstated · 2
- Gap question. The transition supplies no basis for expecting completion, rather than stronger repair, to uniquely restrict harmful cell groups at equal early recovery or to produce a greater lifespan benefit. Establish the missing link before relying on this step.
- Hypothesis. The proposed explanation assumes that prolonged repair allows consequential new LINE-1 insertions in surviving epithelial cell families, that restoring suppression reduces those events, and that those events account for completion's advantage. The supplied sources do not establish those relationships.
How a result here could mislead · 3
- Fewer insertions or smaller harmful cell groups could reflect fewer cell divisions or loss of the affected cells, rather than fewer insertion events during otherwise comparable repair. What closes it: The stipulated equality of total divisions must be verified alongside early recovery, cell survival and persistence of the tracked cell families. New insertions must be distinguished from pre-existing variants by reading the DNA sequence of those families; a copying-activity reporter alone does not establish which permanent insertions remain.
- Smaller harmful cell groups could be credited to prevention of permanent DNA changes even if treatment merely pauses their growth or acts through the competing inflammation-related explanations. What closes it: Growth must be followed after treatment ends, and confirmed new insertions and their effects on cell behavior must be assessed alongside group size. Distinguishing the supplied rivals also requires assessing the alternative completion functions they propose, including cell maturation, inflammatory stimulation and oxygen use.
- A remaining benefit from repair completion after treatment could be read as disproving the LINE-1 explanation even if treatment never adequately suppressed new insertions in the relevant cells. What closes it: A criterion for practically eliminating new LINE-1 insertions must be fixed before interpreting this comparison and verified in the persistent cell families being studied. The supplied specification gives no numerical criterion or validated delivery method for old mice.
What would make this wrong. If timely repair completion retained its advantage in limiting harmful cell-group expansion after new LINE-1 insertions had been practically eliminated in the relevant persistent cells, with early recovery and total divisions matched, the claim that LINE-1 copying determines that advantage would fail. Separately, a reproducible effect of changing the order of otherwise identical repair cycles would reject the borrowed order-independent accumulation model. Neither observation alone would settle whether other ways of completing repair can extend life.
What it would change. If the hypothesis held, the search for interventions that imitate useful bodily processes would gain a specific completion function to reproduce: shutting down mobile-DNA copying after the initial repair response. Comparisons with stronger repair would then need to track lasting genetic changes and later harmful growth, alongside early recovery. Even a successful cell experiment would leave delivery in old mice, differences between species, cancer mortality and lifespan extension unestablished.
Sources read · 6
Altered Methylation Levels in LINE-1 in Dental Pulp Stem Cell-Derived Osteoblasts. · International dental journal · 2025
“This study revealed that DPSC-DOs possessed different LINE-1 methylation than DPSCs.”
Does not settle: The source does not establish LINE-1 expression, retrotransposition or new insertions; regeneration timing or completion; effects in epithelial lineages or pathological clones; acquisition of driver changes; tumour risk or lifespan; or the efficacy, dose, timing and safety of LINE-1-targeting antisense oligonucleotides.
SOX-11 regulates LINE-1 retrotransposon activity during neuronal differentiation. · FEBS letters · 2018
“We also show that SOX-11 protein binding to the LINE-1 promoter is higher in differentiating neuroblastoma cells, while knock-down of SOX-11 inhibits the induction of LINE-1 transcription in differentiating conditions.”
Does not settle: It does not establish LINE-1 activity during epithelial regeneration, whether delayed regeneration increases new insertions, whether late-phase LINE-1 RNA-targeting antisense oligonucleotides reduce insertions, or whether such treatment limits pathological clones, cancer risk, or mortality.
DNA repair protein Rad18 restricts LINE-1 mobility. · Scientific reports · 2018
“Consequently, Rad18 strongly reduced the number of G418-resistant cell colonies (Fig. ), indicating that Rad18 restricts L1 retrotransposition.”
Does not settle: Остаются открытыми связь LINE-1 с продолжительностью регенерации, эффективность антисмысловых олигонуклеотидов в поздней фазе восстановления, влияние на эпителиальные клоны, накопление драйверных изменений, опухолевый риск и продолжительность жизни. Опыты проведены на клетках 293T с подавлением ретротранспозиции белком Rad18.
MxB inhibits long interspersed element type 1 retrotransposition. · PLoS genetics · 2022
“In conclusion, our data support MxB as an anti-LINE-1 factor which functions by sequestering LINE-1 RNPs within the cytoplasmic granules through engaging the stress granule marker proteins G3BP1 and TIA1.”
Does not settle: The source does not establish regeneration-linked LINE-1 activity, effects in persistent epithelial lineages, irreversible driver accumulation, late-phase RNA-targeting antisense oligonucleotide treatment, cancer-risk reduction, SPV_3 stabilization, or lifespan extension.
Post-Transcriptional Control of LINE-1 Retrotransposition by Cellular Host Factors in Somatic Cells. · Frontiers in cell and developmental biology · 2016
“Its overexpression reduces full-length L1 RNA levels, and L1 retrotransposition levels.”
Does not settle: The source does not establish that regeneration creates a defined period of LINE-1 activity, that delayed regeneration increases irreversible insertions in persistent epithelial clones, or that late-phase LINE-1 RNA-targeting antisense oligonucleotides reduce insertions, driver acquisition, tumor risk, SPV_3, or mortality.
Upregulated LINE-1 Activity in the Fanconi Anemia Cancer Susceptibility Syndrome Leads to Spontaneous Pro-inflammatory Cytokine Production. · EBioMedicine · 2016
“Here we show that SLX4 and its upstream activator FANCD2 directly repress LINE-1 retrotransposition and prevent accumulation of cytoplasmic nucleic acids.”
Does not settle: Источник не исследует регенерацию эпителия, её своевременное завершение, позднефазное подавление РНК LINE-1 антисмысловыми олигонуклеотидами, число новых вставок за восстановительный цикл, эволюцию патологических клонов, опухолевый риск или продолжительность жизни.
The gap this hypothesis explains
Two established results predict opposite outcomes, and both cannot be right.
Can mimicking timely repair completion extend life more than boosting repair by limiting later growth of abnormal cell groups?
Original wording · exactly as the pipeline generated it
Может ли миметик своевременного завершения регенерации продлевать жизнь сильнее миметика её усиления, если при одинаковом раннем восстановлении только первый ограничивает последующее расширение патологических клонов?
What this question is asking
The question compares two ways of copying the body's tissue-repair processes: strengthening repair and bringing it to a timely end. It asks whether repeated treatments that promote completion could extend remaining life more than treatments that strengthen repair, when both restore the tissue's protective barrier equally well at first. It assumes that only the completion treatment limits the later expansion of pathological clones, meaning groups of cells descended from one cell that have disease-associated properties. It also asks whether tissue aging changes which phase of repair determines the long-term benefit or harm.
- Mimetic
- An intervention intended to reproduce some effect of a natural biological process. Here it refers to copying either stronger tissue repair or its timely completion; no particular substance or intervention is specified.
- Regeneration or tissue repair
- The processes through which damaged tissue recovers. The question distinguishes an early period of recovery from the later ending of repair activity, without establishing precise boundaries between these phases.
- Timely repair completion
- Ending repair activity at a time that preserves its useful recovery effects. The supplied material does not specify how that time is recognized or measured.
- Tissue barrier
- A tissue's protective separation between compartments or between the body and its surroundings. Restoring this function is the proposed early benefit, but the specific tissue and measurement are not identified.
- Pathological clone
- A group of cells descended from a common ancestor cell and described as having disease-associated properties. Clone expansion means that this group grows; the input does not specify which properties make a clone pathological or whether every such clone leads to cancer.
- Remaining lifespan
- The length of life after a specified starting point, such as treatment initiation. It is distinct from early tissue recovery or the amount of abnormal cell growth.
- Tissue aging
- Changes in tissue as it grows older. The question asks whether these changes alter the treatment comparison, but supplies no age categories or measure of tissue aging.
- Signaling pathway
- A connected sequence of cellular signals that influences what cells do. S4 distinguishes which repair-related pathway is active from how long that activity continues.
- Stem cell
- A cell capable of maintaining a cell supply and producing cells that contribute to tissue renewal. S2's model concerns the subset activated in association with repair, rather than all stem cells.
- Time-weighted measure
- A measure that accounts for how long different values persist. In S2, the prediction concerns activated cell numbers over time rather than a single cell count.
- Inflammation and its resolution
- Inflammation is a biological response to injury or harmful stimuli; resolution is the process by which that response ends. S3 hypothesizes impaired resolution, which is related to, but does not establish, the proposed comparison of repair treatments.
- Mutation
- A change in a cell's genetic material. S3 hypothesizes a type of mutation that interferes with the ending of inflammation.
- Cancer-promoting or carcinogenic
- Contributing to the development of cancer. S4 uses this outcome to distinguish potentially harmful prolonged repair signaling from safe regeneration; it does not measure the lifespan effects of the proposed treatments.
- Acute and chronic injury
- Acute injury occurs over a relatively short period, while chronic injury persists or recurs. These are the injury contexts identified for S4, rather than specified treatment schedules.
At equal early recovery, only a mimetic of timely regeneration completion limits subsequent expansion of pathological clones.
A mimetic is a treatment intended to reproduce a natural process; here, the two processes are strengthening tissue repair and ending it at the appropriate time. The assumption is that both treatments initially restore tissue function equally well, but only the completion treatment restrains later growth of disease-associated cell families. If established, this would make later cell growth a possible explanation for a difference in remaining lifespan.
S4 supports a narrower timing-related proposition: in its discussion of liver cancer, it states that the duration of repair-related signaling determines whether regeneration remains safe or becomes cancer-promoting. It does not establish equal early recovery under two mimetics, or that only a completion mimetic limits pathological clones. S2 supplies a theoretical connection between sustained activation of repair-associated stem cells and cancer risk, rather than evidence for this treatment comparison. The supplied sources therefore support part of the rationale, but not the asserted comparative result.S4S2
The same question asked without the part nothing read establishes:
- When two treatments restore a tissue barrier equally well at first, does mimicking timely repair completion extend remaining life more than strengthening repair?
- How do treatments that promote repair completion versus stronger repair differ in later abnormal cell expansion and remaining lifespan?
- Does tissue aging change the long-term effects of strengthening repair compared with promoting its timely completion?
- Timely completion extends life more Under the question's assumptions, both treatments would deliver the same early recovery, while the completion treatment would leave less subsequent abnormal cell expansion. A longer remaining lifespan would be consistent with that later difference outweighing any benefit of continued repair, although the lifespan difference alone would not prove its cause.
- Both extend life equally Even if the completion treatment limited abnormal cell expansion more effectively, that difference would not produce a greater lifespan benefit over the period measured. Early repair, later cell growth and remaining lifespan would therefore be distinct outcomes rather than interchangeable measures of success.
- Stronger repair extends life more Under the same assumed early recovery and clone-growth difference, stronger repair would nevertheless produce the better survival outcome. This would mean that restricting abnormal cell expansion was insufficient to determine the overall lifespan effect; the supplied sources do not establish what would account for that result.
- The ranking changes with tissue age The same early recovery and later difference in abnormal cell growth could accompany different lifespan rankings in younger and older tissue. A result established at one tissue age would then fail to settle the comparison at another; the supplied sources do not establish whether such a reversal occurs.
The proposed benefit begins with restoring a damaged tissue barrier, allowing the tissue to perform its protective role again. The question then separates that early recovery from what happens to abnormal cell groups afterward. If equally effective early repair is followed by different amounts of harmful cell expansion, early recovery alone would not establish which treatment has the better long-term outcome. However, even less abnormal cell expansion would not by itself establish longer life; that final connection remains unmeasured in the supplied evidence.
S-узлы уровня RL-1 поддерживают усиление регенерации, её последующее торможение и возможность клонального отбора; общий долгосрочный исход неизвестен.
Повторные циклы миметика восстанавливают барьер и увеличивают оставшуюся жизнь при отсутствии ускоренного расширения патологических клонов.
Не установлено, какая фаза определяет знак долгосрочного эффекта при одинаковой ранней пользе и меняется ли это со старением ткани.
The mechanism it proposes
The engine's own statement of the hypothesis, in full.
Миметик своевременного завершения регенерации может превосходить её усиление потому, что сокращает периоды активности мобильных элементов LINE-1. Во время каждого затянутого восстановительного цикла новые вставки необратимо изменяют геномы сохраняющихся эпителиальных линий. Возвращение к зрелой программе должно уменьшать число таких событий на цикл и тем самым замедлять появление дополнительных драйверных изменений внутри уже существующих патологических клонов. Физиологический прототип — повторное подавление мобильных элементов после восстановления ткани. Кандидатный миметик — кратковременное подавление активных LINE-1 с помощью направленных на их РНК антисмысловых олигонуклеотидов в поздней фазе восстановления. Он должен воспроизводить эту функцию завершения даже при сохранённом раннем регенеративном импульсе. Стабилизируется SPV_3; предполагаемое продление жизни связано со снижением позднего опухолевого риска.
Where the idea comes from
The hypothesis borrows a result from another field. This is what it borrows, and from where.
Механика усталости материалов: правило Пальмгрена–Майнера D = Σ(i=1…k) n_i/N_i. Здесь k — число заранее заданных классов регенеративного воздействия; i — индекс класса; n_i — фактическое число завершённых циклов этого класса; N_i — независимо оценённое среднее число циклов до первого функционально подтверждённого патогенного события LINE-1 при повторении только этого класса; D — безразмерная накопленная нагрузка. Для биологического переноса дополнительно предполагается независимый пуассоновский риск событий: тогда вероятность хотя бы одного события равна 1 − exp(−D), а D = 1 соответствует приблизительно63%, а не гарантированному отказу ткани. Это проверяемая модель необратимого накопления геномных повреждений. Её отличительное ограничение — независимость результата от порядка одинаковых циклов. [Исследование моделей накопления усталостного повреждения](https://www.mdpi.com/2075-4701/8/6/456).
Testing and possible results
The prediction that would tell it apart
A hypothesis that predicts what its rivals predict is not worth running an experiment over. This is the observation on which this one differs.
При равном суммарном числе делений позднее подавление LINE-1 уменьшит число новых подтверждённых вставок и патологическое расширение линий, сохранив раннее восстановление. Оно также устранит дополнительное преимущество миметика завершения, если оба действуют через один механизм. Напротив, сохранение преимущества завершения при практически устранённой ретротранспозиции опровергнет её определяющую роль. Перестановка последовательности циклов при одинаковом наборе нагрузок отдельно проверит предсказание модели накопления.
States a measurable outcome; comparing rivals needs more conditions. The chunk specifies comparative outcomes, a conditional disappearance of an advantage, and an explicit rejection condition. The final sentence proposes a test but does not state its predicted outcome. No rival prediction is supplied. Only a bench experiment would settle it.
What testing it would take
The engine's own read on whether this is testable with methods that already exist.
Новые вставки можно отличать от исходных вариантов посредством секвенирования отдельных линий и репортёров ретротранспозиции. Клеточные эксперименты осуществимы; адресная доставка олигонуклеотидов и перенос результата на старых мышей требуют разработки. Активность LINE-1 и её регуляция различаются между видами.
Other explanations
Every other hypothesis the engine wrote for the same gap, and the observation that would separate the two.
При равном суммарном числе делений позднее подавление LINE-1 уменьшит число новых подтверждённых вставок и патологическое расширение линий, сохранив раннее восстановление. Оно также устранит дополнительное преимущество миметика завершения, если оба действуют через один механизм. Напротив, сохранение преимущества завершения при практически устранённой ретротранспозиции опровергнет её определяющую роль. Перестановка последовательности циклов при одинаковом наборе нагрузок отдельно проверит предсказание модели накопления.
- Rival 01 of 04What would separate them
Brief breaks in genetic material may complete intestinal cell maturation and curb harmful growth predicts: При одинаковом раннем восстановлении и одинаковом позднем снижении пролиферации выключение каталитической активности CAD устранит устойчивую дифференцировку и последующее ограничение патологических линий. Возвращение кратковременной активности нормального CAD восстановит оба эффекта; каталитически неактивный вариант окажется бесполезен. Решающее наблюдение: клетки с зарегистрированными кратковременными разрывами останутся живыми, завершат дифференцировку и дадут меньше патологических потомков. Если они преимущественно погибают либо польза сохраняется при выключенном CAD, предложенный механизм опровергнут.
- Rival 02 of 04What would separate them
Restoring intestinal alkaline phosphatase may limit pathological growth after regeneration predicts: При одинаковой проницаемости эпителия, одинаковом содержании кислорода и одинаковом количестве бактерий активный фермент уменьшит воспалительную активность кишечного содержимого и позднее расширение патологических линий; каталитически неактивный фермент этого не сделает. Подавление эндогенной кишечной щелочной фосфатазы устранит преимущество завершения, а добавление активного фермента восстановит его. Сохранение преимущества при отсутствии измеримого дефосфорилирования опровергнет гипотезу.
- Rival 03 of 04What would separate them
Restoring oxygen consumption in colon cells may limit pathological clones after regeneration predicts: При одинаковом раннем восстановлении и сохранённой активности кишечной щелочной фосфатазы преимущество позднего миметика исчезнет при избирательном подавлении окислительного обмена колоноцитов. Независимое восстановление низкой доступности кислорода вернёт защиту. В определённом микробном сообществе замена бактерий на сопоставимые варианты, лишённые соответствующего преимущества дыхания, должна резко уменьшить различие между усилением и завершением регенерации. Если защита сохраняется при экспериментально фиксированных кислороде и бактериальном дыхании, гипотеза опровергнута.
- What would separate them
A late aryl hydrocarbon receptor signal may pause clone growth without extending life predicts: После полного прекращения воздействия патологические линии из обеих групп покажут сопоставимую способность к повторному росту в общей среде и сопоставимую опухолеобразующую способность. При продолжительном наблюдении до конца жизни различие в размерах клонов не перейдёт в преимущество общей выживаемости. Устойчивое уменьшение опухолевого потенциала после отмены вместе с увеличением оставшейся жизни опровергнет эту гипотезу в пользу одного из механизмов полноценного завершения.
What stands behind it
Which of the figures above have a study behind them, which are the engine's own, and what it would take to refute the hypothesis. This audit never judges the idea.
1 quantitative figure appears below and the hypothesis cites no study for any of them. They are the engine's own, and the marks in the text say which.
What it would take to refute it. Nothing already retrieved carries the prediction’s terms and it names no measurement this layer can route to a public dataset, so the bench is the residual — not a finding against it.
0 citation handles extracted; 1 Europe PMC search run; 0 records examined; 0 sources stored for enrichment, 0 with full text. A citation that did not resolve is a bibliographic failure, not proof that no such paper exists, and no hypothesis is blocked by this audit.